Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × INDUSTRY × inavolisib × Clear all

Phase

Status

Recruiting 12 Active not recruiting 6 Withdrawn 1 Completed 1

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Paclitaxel 486 Carboplatin 431 Gemcitabine 389 Docetaxel 383 Cisplatin 356 pembrolizumab 336 Bevacizumab 334 Nivolumab 259 Pemetrexed 242 Capecitabine 221 Fluorouracil 211 Dexamethasone 211 Rituximab 202 Trastuzumab 193 Cyclophosphamide 187 Oxaliplatin 160 Erlotinib Hydrochloride 146 atezolizumab 145 Ipilimumab 145 Prednisone 144 Cetuximab 141 Irinotecan 138 Leucovorin 130 Doxorubicin 129 Sorafenib 120 Lenalidomide 117 Bortezomib 117 Sunitinib 107 Everolimus 93 Radiotherapy 89

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04632992 2025-01-08

MyTACTIC

Genentech, Inc.

Phase 2 Completed

252 enrolled 27 charts

Advanced Unresectable or Metastatic Solid Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡